LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

Home・Aandelen Lijst・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Open

SectorGezondheidszorg

3.68 3.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.45

Max

3.68

Belangrijke statistieken
By Trading Economics
Inkomsten	-9.4M -118M
Verkoop	-29M 6.5M
EPS	-0.22
Winstmarge	-1,815.575
Werknemers	600
EBITDA	-20M -109M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+105.57% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-270M 1.6B
Vorige openingsprijs	0.6
Vorige sluitingsprijs	3.68

Nieuwssentiment

By Acuity

100%

320 / 344 Rangschikking in Healthcare

Recursion Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 feb 2026, 21:28 UTC

Acquisities, Fusies, Overnames

Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street. -- Barrons.com

19 feb 2026, 10:27 UTC

Acquisities, Fusies, Overnames

Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street. -- Barrons.com

18 feb 2026, 14:52 UTC

Acquisities, Fusies, Overnames

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia. -- Barrons.com

Peer Vergelijking

Prijswijziging

Recursion Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

105.57% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7.38 USD 105.57%

Hoogste 10 USD

Laagste 5.5 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Recursion Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Recursion Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

320 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.